ClinicalTrials.gg
CompletedNCT03596905(IBS-C)Updated Dec 31, 2025Results posted

Efficacy and Safety of Plecanatide in Children 6 to <18 Years With Irritable Bowel Syndrome With Constipation (IBS-C)

A Phase 2 interventional study of Plecanatide and Matching placebo in Irritable Bowel Syndrome With Constipation, sponsored by Bausch Health Americas, Inc.. Completed at 35 sites in United States. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
218
Allocation
Randomized
Ages
6 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing plecanatide in Constipation — none open to participants now, 1 under way, none of them phase 3. plecanatide · Constipation.

Enrollment
9th of 12
218 · median 800
Started
2018
the only one that year
Phase 2
5 of 12
none open now
Registered
10th of 12
by date
Lead sponsor
11 of 12
Bausch Health Americas, Inc.

Among the 12 studies testing plecanatide in Constipation, this one is the 9th largest by enrollment, is the only one that started in 2018, is one of 5 in phase 2, and was the 10th registered.

Constipation

1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.

Browse Constipation studies →

Open to participants now

None of the 12 studies testing plecanatide in Constipation is open now. The open studies under Constipation, anywhere →

Where they have run

About plecanatide

plecanatide: first FDA approval 2017 (TRULANCE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 6 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing plecanatide in Constipation as a file.
02

Study summary

The goal of this clinical trial is to learn if plecanatide can improve bowel function and relieve symptoms of irritable bowel syndrome with constipation (IBS-C) in children and adolescents aged 6 to \<18 years. The main questions it aims to answer are:

  • Does plecanatide increase the number of spontaneous bowel movements (SBMs) compared to placebo?
  • Is plecanatide safe and well tolerated in this pediatric population? Researchers will compare plecanatide at different doses to a placebo (a look-alike substance with no active drug) to see if plecanatide improves bowel function.

Participants will:

  • Take plecanatide or placebo orally once daily for 4 weeks
  • Complete daily symptom diaries
  • Attend clinic visits for assessments and safety checks
Read the detailed description

This study is a randomized, double-blind, placebo-controlled, dose-ranging clinical trial designed to evaluate the safety, efficacy, and pharmacokinetics of plecanatide in pediatric patients aged 6 to \<18 years with irritable bowel syndrome with constipation (IBS-C). IBS-C is a condition that causes abdominal pain and infrequent, hard bowel movements.

The study includes two age cohorts:

Group A: 6 to 11 years Group B: 12 to \<18 years

Participants are randomly assigned to receive one of four plecanatide doses (0.5 mg, 1.0 mg, 2.0 mg, or 3.0 mg) or placebo. All treatments were taken orally once daily for 4 weeks following a 28-day screening/baseline period. After treatment, participants were followed for 2 weeks.

The primary objective is to determine whether plecanatide increases the number of spontaneous bowel movements (SBMs) compared to placebo.

Secondary objectives include:

Time to first bowel movement after starting treatment Changes in stool consistency Changes in abdominal pain and discomfort Overall safety and tolerability of plecanatide

Safety assessments include monitoring adverse events, laboratory tests, and treatment compliance. Participants recorded daily bowel habits and symptoms in an electronic diary and attended scheduled clinic visits for evaluations.

03

Conditions studied

  • Irritable Bowel Syndrome With Constipation
04

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A patient will be eligible for study participation if he or she meets all of the following criteria:

  1. Male or female child or adolescent age 6 to \< 18;
  2. Meets ROME IV criteria for child/adolescent IBS-C defined as:

For at least 2 months before diagnosis the patient has had:

  1. Abdominal pain at least 4 days per month associated with one or more of the following:

    1. Related to defecation
    2. A change in frequency of stool
    3. A change in form (appearance) of stool;
  2. The pain does not resolve with resolution of the constipation (children in whom the pain resolves have functional constipation, not irritable bowel syndrome);
  3. After appropriate evaluation, the symptoms cannot be fully explained by another medical condition
  4. More than one-fourth (25%) of bowel movements with Bristol stool form types 1 or 2 and less than one-fourth (25%) of bowel movements with Bristol stool form types 6 or 7 on the BSFS or 4 or 5 on the mBSFS-C;

3. Patient's parent/guardian/LAR is able to voluntarily provide written, signed, and dated consent and patient is able to voluntarily provide assent as per IRB guidance; 4. Patient and patient's parent/guardian/LAR demonstrates an understanding, ability, and willingness to fully comply with protocol requirements and study procedures (e.g., acceptance of venipuncture, acceptance of urine drug screen for opiates, visit schedule, complete daily electronic diary reporting).

Exclusion criteria

EXCLUSION CRITERIA

A patient will be excluded from the study if he or she meets any of the following criteria:

  1. The patient has a mental age \<4 years in the investigator's opinion;
  2. The patient has previously been diagnosed with anorectal malformations, neurological deficits, or anatomical anomalies that would constitute a predisposition to constipation;
  3. The patient currently requires iron supplements, amitriptyline, or other tricyclic antidepressants for depression, opioid-containing medications or compounds for pain, or has other conditions that require medications known to cause constipation. A patient with an onset of constipation prior to the use of these medications and who has been on a stable dose for at least 8 weeks prior to Screening might be considered eligible for this study if the investigator deems these medications do not significantly contribute to the patient's constipation. Screening of these patients needs to be approved by the medical monitor and the sponsor;
  4. The patient is pregnant or lactating;
  5. Females age 12 to \< 18 or females age 6 to 11 of (defined as post menarche) who does not agree to practice one of the following medically acceptable methods of throughout the study;

    • Hormonal methods such as oral, implantable, injectable, vaginal ring, or transdermal contraceptives for a minimum of 1 full cycle (based on the patient's usual menstrual cycle period) before study drug administration.
    • Total abstinence from sexual intercourse (since the last menses before study drug administration
    • Intrauterine device.
    • Double-barrier method (condoms, sponge, or diaphragm with spermicidal jellies or cream.
  6. The patient follows a diet not considered normal by the investigator for the patient's age, relative to variety of food, caloric content, and quantity. The patient must have been on a stable diet for at least 30 days prior to Screening;
  7. The patient's mobility or normal exercise tolerance is compromised in the investigator's opinion;
  8. The patient has a history of an eating disorder;
  9. The patient has clinical or laboratory signs and symptoms of significant cerebral, respiratory, renal, hepatobiliary, pancreatic, intestinal (including acute appendicitis, inflammatory bowel disease, or undiagnosed abdominal pain), endocrinologic, or infectious disease that in the investigator's judgment could interfere with study assessments or completion of the study. (Note: A patient with a history of thyroid disease may be enrolled if he or she has normal T3 and T4 at Screening. If the patient is taking medication for active thyroid disease, his or her T3 and T4 level must be within normal limits and the dose of any medication used to treat it must be stable for at least 30 days prior to Screening);
  10. The patient has any other medical condition or is receiving concomitant medication or therapy that would in the investigator's opinion compromise his or her safety or compliance with the study protocol or compromise data collection;
  11. The patient has a history or evidence of drug or alcohol abuse in the 12 months before Screening;
  12. The patient has a , allergy, or to plecanatide;
  13. The patient has received any experimental drug, including linaclotide and lubiprostone, or experimental therapy within 30 days of study start;
  14. The patient is unable to tolerate protocol-prescribed rescue medication (Dulcolax®), or unwilling to use it as the only laxative for the duration of the trial;
  15. The patient has taken a medication considered to be a protocol-defined prohibited prior or concomitant medication or supplement as defined in section 3.3.2;
  16. The patient and his or her caregiver are unable to communicate well with the study staff and comply with the study requirements (restrictions, appointments, and examination schedule). (The patient/caregiver must be able to complete required Daily BM and Symptom diary entries during the Screening/Baseline period and for the duration of the study. The patient/caregiver must also agree to provide contact information to receive daily reminders should the patient not complete the daily electronic diary entries or require password resets);
  17. The patient has been screened for or participated in this or another Synergy study in the past;
  18. The patient has a sibling that is currently participating or has participated in another Synergy study.

    Exclusion Criteria Based on Baseline Diary Entries

  19. Patient reports having more than 1 loose, mushy stool (Diary-recorded stool consistency of 6 on the Bristol Stool Form Scale (BSFS or 4 on the modified Bristol Stool Form Scale for Children [mBSFSC]) or any watery stool (Diary-recorded stool consistency of 7 on the BSFS or 5 on the mBSFS-C) with any SBM that occurred in the absence of laxative use on the calendar day of the BM or the calendar day before the BM during each 7-day (week) period before the randomization day and up to the day of randomization;
  20. ≥ 3 CSBMs per week for either week of the 2-week baseline diary assessment immediately preceding the randomization visit;
  21. > 6 SBMs per week for either week of the 2-week baseline diary assessment immediately preceding the randomization visit;
  22. Patient reports worst abdominal pain intensity (WAPI) scores in the 2-week baseline diary that meet either of the following:

    1. WAPI score of 0 on the 11-point Numeric Rating Scale or Wong-Baker Faces® Pain Rating Scale for more than two days during each week of the 2-week baseline diary period.
    2. An average WAPI \< 3 for either of the two weeks of the baseline diary;
  23. Completion of \< 5 of the 7 required daily diary entries in each week of the 2-week baseline diary assessment immediately preceding the randomization visit;
  24. Use of rescue medication (Dulcolax®, bisacodyl) for more than 2 days during either of the two weeks of the 2-week baseline diary assessment immediately preceding the randomization visit.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
218 participants (actual)

Study arms

  • Experimental
    0.5 mg plecanatide

    Plecanatide 0.5 mg Taken orally once daily for 4 weeks Group A: 6 to 11 years old

    Drug: Plecanatide

  • Experimental
    1.0 mg plecanatide - Group A

    Plecanatide 1.0 mg Taken orally daily for 4 weeks Group A: 6 to 11 years old

    Drug: Plecanatide

  • Experimental
    2.0 mg plecanatide

    Plecanatide 2.0 mg Taken orally daily for 4 weeks Group B: 12 to 18 Years of Age

    Drug: Plecanatide

  • Experimental
    3.0 mg plecanatide

    Plecanatide 3.0 mg Taken orally daily for 4 weeks Group B: 12 to \< 18 years old

    Drug: Plecanatide

  • Placebo comparator
    Matching placebo - Group A

    Matching placebo Taken orally daily for 4 weeks Group A: 6 to 11 years old

    Drug: Matching placebo

  • Experimental
    1.0 mg plecanatide - Group B

    Plecanatide 1.0 mg Taken orally daily for 4 weeks Group B: ≥ 12 to \< 18 Years of Age

    Drug: Plecanatide

  • Placebo comparator
    Matching Placebo - Group B

    Matching placebo Taken orally daily for 4 weeks Group B: 12 to \< 18 years old

    Drug: Matching placebo

Interventions

  • Taken orally daily for 4 weeks

    Also known as: Trulance

  • DrugMatching placebo

    Taken orally daily for 4 weeks

    Also known as: No other names

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Weekly Spontaneous Bowel Movement (SBM) Frequency Over the 4 Week Treatment Period Compared to Placebo and Across Treatment Groups

    Weekly SBM rate computed for each week

    Time frame: Baseline to Week 4

Secondary outcomes

  1. Change From Baseline in Frequency of Abdominal Pain and Abdominal Discomfort Over the 4-week Treatment Period Compared to Placebo and Across Treatment Groups..

    Weekly frequency was calculated as the number of abdominal pain episodes and abdominal discomfort episodes per week, based on daily diary entries. Baseline was the average weekly frequency during the 2-week baseline assessment period. Values shown are mean change from baseline (SD).

    Time frame: Baseline to Week 4

  2. Change From Baseline in Severity of Abdominal Pain and Abdominal Discomfort Over the 4-week Treatment Period Compared to Placebo and Across Treatment Groups..

    Severity of abdominal pain and abdominal discomfort was recorded daily using an electronic diary on a 0-10 numeric rating scale (0 = no pain/discomfort; 10 = worst possible). Weekly averages were calculated; baseline was the average score during the 2-week baseline period. Values shown are mean change from baseline.

    Time frame: Baseline to Week 4

  3. Change From Baseline in Frequency of Complete Spontaneous Bowel Movements (CSBM)

    Weekly frequency of complete spontaneous bowel movements (CSBMs) was calculated based on daily diary entries. Baseline was the average weekly frequency during the 2-week baseline period. Values shown are mean change from baseline (SD) at end of 4 weeks of study.

    Time frame: Baseline to Week 6

  4. Change From Baseline in Frequency of Bowel Movements (BM)

    Weekly frequency of bowel movements (BMs) was calculated based on daily diary entries. Baseline was the average weekly frequency during the 2-week baseline period. Values shown are mean change from baseline (SD).

    Time frame: Baseline to Week 4

  5. Time to First Bowl Movement (in Days)

    This outcome was analyzed as a time-to-event variable (time to first complete spontaneous bowel movement), and confidence intervals were estimated using Kaplan-Meier methods.

    Time frame: Day 1 to first BM during Treatment Period

  6. Change From Baseline in Stool Consistency (Based on Bristol Stool Form Scale, BSFS or Modified Bristol Stool Form Scale for Children, mBSFS-C)

    Weekly stool consistency scores based on BSFS (≥12 years) or mBSFS-C (6-11 years). BSFS Scale is a 7 point scale, from Type 1 (Hard to pass) to Type 7 (entirely liquid). mBSFS-C is a 5 point scale, from Type 1 (hard to pass) to Type 5 (watery, no solid pieces).

    Time frame: Baseline to Week 4

  7. Use of Rescue Medication

    Number of rescue medication tablets (Dulcolax® 5 mg) used during the 4-week treatment period. Subjects were instructed to use rescue medication only if ≥72 hours had passed since last bowel movement.

    Time frame: Baseline to Week 4

  8. Change From Baseline in Frequency of Fecal Incontinence

    Weekly fecal incontinence episodes recorded in daily diary.

    Time frame: Baseline to Week 4

  9. Change From Baseline in Severity of Defecation Pain

    Severity of abdominal pain scored daily on a 0-10 numeric rating scale (0 = no pain, 10 = worst possible pain). Weekly averages were calculated from daily scores.

    Time frame: Baseline to Week 4

  10. Change From Baseline in Frequency of Pain With Defecation

    Pain with defecation was recorded in daily diaries as the number of episodes per week. Results represent the mean change from baseline in weekly frequency.

    Time frame: Baseline to Week 4

  11. Change From Baseline in Frequency of Large Diameter Stools

    Weekly frequency of large diameter stools recorded in daily diary.

    Time frame: Baseline to Week 4

07

Results

Posted Dec 31, 2025

Participant flow

Participant flow — Overall Study
Milestone0.5 mg Plecanatide1.0 mg Plecanatide - Group AMatching Placebo - Group A1.0 mg Plecanatide - Group B2.0 mg Plecanatide3.0 mg PlecanatideMatching Placebo - Group B
Started30292934323232
Completed29262834273129
Not completed1310513
Withdrew: Protocol violation0000100
Withdrew: Withdrawal by subject0210200
Withdrew: Participant moved and was unable to complete study0100000
Withdrew: Adverse event0000001
Withdrew: Non-compliance with ediary1000102
Withdrew: Non-compliance with study drug0000100
Withdrew: Lost to follow-up0000010

Outcome measures

PrimaryChange From Baseline in Weekly Spontaneous Bowel Movement (SBM) Frequency Over the 4 Week Treatment Period Compared to Placebo and Across Treatment Groups

Weekly SBM rate computed for each week

Time frame:
Baseline to Week 4
Reported as:
Mean · Number of SBMs per week
Change From Baseline in Weekly Spontaneous Bowel Movement (SBM) Frequency Over the 4 Week Treatment Period Compared to Placebo and Across Treatment Groups
Number of SBMs per weekExperimental: 0.5 mg plecanatideExperimental: 1.0 mg plecanatide - Group AMatching placebo - Group AExperimental: 1.0 mg plecanatide - Group BExperimental: 2.0 mg plecanatideExperimental: 3.0 mg plecanatideMatching Placebo - Group B
Change From Baseline in Weekly Spontaneous Bowel Movement (SBM) Frequency Over the 4 Week Treatment Period Compared to Placebo and Across Treatment Groups0.6 ± 2.240.8 ± 1.750.6 ± 1.531.0 ± 2.081.1 ± 2.20.70 ± 2.45-0.2 ± 1.95
SecondaryChange From Baseline in Frequency of Abdominal Pain and Abdominal Discomfort Over the 4-week Treatment Period Compared to Placebo and Across Treatment Groups..

Weekly frequency was calculated as the number of abdominal pain episodes and abdominal discomfort episodes per week, based on daily diary entries. Baseline was the average weekly frequency during the 2-week baseline assessment period. Values shown are mean change from baseline (SD).

Time frame:
Baseline to Week 4
Reported as:
Mean · Episodes per week
Change From Baseline in Frequency of Abdominal Pain and Abdominal Discomfort Over the 4-week Treatment Period Compared to Placebo and Across Treatment Groups..
Episodes per weekExperimental: 0.5 mg plecanatideExperimental: 1.0 mg plecanatide - Group AMatching placebo - Group AExperimentaL: 1.0 mg plecanatide - Group BExperimental: 2.0 mg plecanatideExperimental: 3.0 mg plecanatideMatching placebo - Group B
Frequency of Abdominal Pain-2.7 ± 2.27-2.2 ± 2.38-1.4 ± 2.47-1.3 ± 1.49-1.6 ± 2.34-1.4 ± 2.26-1.6 ± 2.56
Frequency of Abdominal Discomfort-2.5 ± 2.18-2.1 ± 2.35-1.3 ± 2.44-0.9 ± 1.59-1.5 ± 2.22-1.1 ± 2.03-1.3 ± 2.43
SecondaryChange From Baseline in Severity of Abdominal Pain and Abdominal Discomfort Over the 4-week Treatment Period Compared to Placebo and Across Treatment Groups..

Severity of abdominal pain and abdominal discomfort was recorded daily using an electronic diary on a 0-10 numeric rating scale (0 = no pain/discomfort; 10 = worst possible). Weekly averages were calculated; baseline was the average score during the 2-week baseline period. Values shown are mean change from baseline.

Time frame:
Baseline to Week 4
Reported as:
Mean · Severity score (0-10 scale)
Change From Baseline in Severity of Abdominal Pain and Abdominal Discomfort Over the 4-week Treatment Period Compared to Placebo and Across Treatment Groups..
Severity score (0-10 scale)Experimental: 0.5 mg plecanatideExperimental: 1.0 mg plecanatide - Group AMatching placebo - Group AExperimentaL: 1.0 mg plecanatide - Group BExperimental: 2.0 mg plecanatideExperimental: 3.0 mg plecanatideMatching placebo - Group B
Severity of Abdominal Pain-3.3 ± 3.07-2.3 ± 2.72-2.3 ± 2.33-2.2 ± 2.37-2.8 ± 2.19-2.56 ± 2.27-2 ± 2.36
Severity of Abdominal Discomfort-3.4 ± 2.97-2.4 ± 2.83-2.40 ± 2.51-1.9 ± 2.58-3.0 ± 2.23-2.5 ± 2.36-2.0 ± 2.46
SecondaryChange From Baseline in Frequency of Complete Spontaneous Bowel Movements (CSBM)

Weekly frequency of complete spontaneous bowel movements (CSBMs) was calculated based on daily diary entries. Baseline was the average weekly frequency during the 2-week baseline period. Values shown are mean change from baseline (SD) at end of 4 weeks of study.

Time frame:
Baseline to Week 6
Reported as:
Mean · Change in Number of CSBMs per week
Change From Baseline in Frequency of Complete Spontaneous Bowel Movements (CSBM)
Change in Number of CSBMs per weekExperimental: 0.5 mg plecanatideExperimental: 1.0 mg plecanatide - Group AMatching placebo - Group AExperimental: 1.0 mg plecanatide - Group BExperimental: 2.0 mg plecanatideExperimental: 3.0 mg plecanatideMatching placebo - Group B
Change From Baseline in Frequency of Complete Spontaneous Bowel Movements (CSBM)0.7 ± 1.730.2 ± 0.750.2 ± 0.910.4 ± 0.850.1 ± 1.070.7 ± 1.79-0.1 ± 0.47
SecondaryChange From Baseline in Frequency of Bowel Movements (BM)

Weekly frequency of bowel movements (BMs) was calculated based on daily diary entries. Baseline was the average weekly frequency during the 2-week baseline period. Values shown are mean change from baseline (SD).

Time frame:
Baseline to Week 4
Reported as:
Mean · Number of BMs per week
Change From Baseline in Frequency of Bowel Movements (BM)
Number of BMs per weekExperimental: 0.5 mg plecanatideExperimental: 1.0 mg plecanatide - Group AMatching placebo - Group AExperimental: 1.0 mg plecanatide - Group BExperimental: 2.0 mg plecanatideExperimental: 3.0 mg plecanatideMatching placebo - Group B
Change From Baseline in Frequency of Bowel Movements (BM)0.5 ± 2.240.8 ± 1.70.6 ± 1.520.8 ± 2.061.0 ± 2.230.8 ± 2.2630 ± 2.05
SecondaryTime to First Bowl Movement (in Days)

This outcome was analyzed as a time-to-event variable (time to first complete spontaneous bowel movement), and confidence intervals were estimated using Kaplan-Meier methods.

Time frame:
Day 1 to first BM during Treatment Period
Reported as:
Median · Days
Time to First Bowl Movement (in Days)
DaysExperimental: 0.5 mg plecanatideExperimental: 1.0 mg plecanatide - Group AMatching placebo - Group AExperimental: 1.0 mg plecanatide - Group BExperimental: 2.0 mg plecanatideExperimental: 3.0 mg plecanatideMatching Placebo - Group B
Time to First Bowl Movement (in Days)4.1 (1.13 to 11.43)2.58 (1.56 to 6.21)5.35 (2.35 to NA)1.68 (0.99 to 5.23)2.05 (0.86 to 6.25)2.57 (0.89 to 8.15)2.69 (1.35 to 5.28)
SecondaryChange From Baseline in Stool Consistency (Based on Bristol Stool Form Scale, BSFS or Modified Bristol Stool Form Scale for Children, mBSFS-C)

Weekly stool consistency scores based on BSFS (≥12 years) or mBSFS-C (6-11 years). BSFS Scale is a 7 point scale, from Type 1 (Hard to pass) to Type 7 (entirely liquid). mBSFS-C is a 5 point scale, from Type 1 (hard to pass) to Type 5 (watery, no solid pieces).

Time frame:
Baseline to Week 4
Reported as:
Mean · Score (BSFS or mBSFS-C)
Change From Baseline in Stool Consistency (Based on Bristol Stool Form Scale, BSFS or Modified Bristol Stool Form Scale for Children, mBSFS-C)
Score (BSFS or mBSFS-C)Experimental: 0.5 mg plecanatideExperimental: 1.0 mg plecanatide - Group AMatching placebo - Group AExperimental: 1.0 mg plecanatide - Group BExperimental: 2.0 mg plecanatideExperimental: 3.0 mg plecanatideMatching placebo - Group B
Change From Baseline in Stool Consistency (Based on Bristol Stool Form Scale, BSFS or Modified Bristol Stool Form Scale for Children, mBSFS-C)1.2 ± 1.120.8 ± 1.181.2 ± 0.721.1 ± 1.241.4 ± 1.51.9 ± 1.350.7 ± 0.96
SecondaryUse of Rescue Medication

Number of rescue medication tablets (Dulcolax® 5 mg) used during the 4-week treatment period. Subjects were instructed to use rescue medication only if ≥72 hours had passed since last bowel movement.

Time frame:
Baseline to Week 4
Reported as:
Mean · Number of Tablets
Use of Rescue Medication
Number of TabletsExperimental: 0.5 mg plecanatideExperimental: 1.0 mg plecanatide - Group AMatching placebo - Group AExperimental: 1.0 mg plecanatide - Group BExperimental: 2.0 mg plecanatideExperimental: 3.0 mg plecanatideMatching Placebo - Group B
Use of Rescue Medication1.3 ± 3.60.7 ± 3.220.4 ± 1.182.4 ± 8.730.2 ± 0.591.6 ± 5.022.4 ± 6.68
SecondaryChange From Baseline in Frequency of Fecal Incontinence

Weekly fecal incontinence episodes recorded in daily diary.

Time frame:
Baseline to Week 4
Reported as:
Mean · Number of episodes per week
Change From Baseline in Frequency of Fecal Incontinence
Number of episodes per weekExperimental: 0.5 mg plecanatideExperimental: 1.0 mg plecanatide - Group AMatching placebo - Group AExperimental: 1.0 mg plecanatide - Group BExperimental: 2.0 mg plecanatideExperimental: 3.0 mg plecanatideMatching Placebo - Group B
Change From Baseline in Frequency of Fecal Incontinence0.3 ± 2.101.9 ± 4.361.1 ± 3.040.9 ± 2.582.3 ± 5.331.0 ± 2.731.3 ± 3.29
SecondaryChange From Baseline in Severity of Defecation Pain

Severity of abdominal pain scored daily on a 0-10 numeric rating scale (0 = no pain, 10 = worst possible pain). Weekly averages were calculated from daily scores.

Time frame:
Baseline to Week 4
Reported as:
Mean · Severity Score 0-10 scale
Change From Baseline in Severity of Defecation Pain
Severity Score 0-10 scaleExperimental: 0.5 mg plecanatideExperimental: 1.0 mg plecanatide - Group AMatching placebo - Group AExperimental: 1.0 mg plecanatide - Group BExperimental: 2.0 mg plecanatideExperimental: 3.0 mg plecanatideMatching Placebo - Group B
Change From Baseline in Severity of Defecation Pain-2.4 ± 3.13-2.6 ± 3.16-2.6 ± 3.62-2.3 ± 2.98-2.5 ± 2.17-1.8 ± 2.7-1.6 ± 2.83
SecondaryChange From Baseline in Frequency of Pain With Defecation

Pain with defecation was recorded in daily diaries as the number of episodes per week. Results represent the mean change from baseline in weekly frequency.

Time frame:
Baseline to Week 4
Reported as:
Mean · Change in Episodes per week
Change From Baseline in Frequency of Pain With Defecation
Change in Episodes per weekExperimental: 0.5 mg plecanatideExperimental: 1.0 mg plecanatide - Group AMatching placebo - Group AExperimental: 1.0 mg plecanatide - Group BExperimental: 2.0 mg plecanatideExperimental: 3.0 mg plecanatideMatching Placebo - Group B
Change From Baseline in Frequency of Pain With Defecation-0.3 ± 2.64-0.8 ± 2.97-0.3 ± 2.910.4 ± 2.33-0.5 ± 2.29-0.8 ± 2.55-0.7 ± 2.58
SecondaryChange From Baseline in Frequency of Large Diameter Stools

Weekly frequency of large diameter stools recorded in daily diary.

Time frame:
Baseline to Week 4
Reported as:
Mean · Number of episodes per week
Change From Baseline in Frequency of Large Diameter Stools
Number of episodes per weekExperimental: 0.5 mg plecanatideExperimental: 1.0 mg plecanatide - Group AMatching placebo - Group AExperimental: 1.0 mg plecanatide - Group BExperimental: 2.0 mg plecanatideExperimental: 3.0 mg plecanatideMatching Placebo - Group B
Change From Baseline in Frequency of Large Diameter Stools0 ± .280 ± 0.480.1 ± 0.570.0 ± 0.61-0.1 ± 0.490.0 ± 0.400.1 ± 0.67

Adverse events

Collected over From consent signature until end of study participation, up to 10 weeks. This includes screening, 4-week treatment, and 2-week follow-up periods.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental: 0.5 mg Plecanatide0/30 (0%)0/30 (0%)2/30 (6.7%)
Experimental: 1.0 mg Plecanatide - Group A0/29 (0%)0/29 (0%)5/29 (17.2%)
Matching Placebo - Group A0/29 (0%)0/29 (0%)1/29 (3.4%)
Experimental: 1.0 mg Plecanatide - Group B0/34 (0%)0/34 (0%)7/34 (20.6%)
Experimental: 2.0 mg Plecanatide0/32 (0%)0/32 (0%)3/32 (9.4%)
Experimental: 3.0 mg Plecanatide0/32 (0%)0/32 (0%)3/32 (9.4%)
Matching Placebo - Group B0/32 (0%)0/32 (0%)2/32 (6.3%)
Most frequent other events
Showing 10 of 21
Most frequent other events
EventExperimental: 0.5 mg PlecanatideExperimental: 1.0 mg Plecanatide - Group AMatching Placebo - Group AExperimental: 1.0 mg Plecanatide - Group BExperimental: 2.0 mg PlecanatideExperimental: 3.0 mg PlecanatideMatching Placebo - Group B
HeadacheNervous system disorders0/302/290/291/341/321/321/32
Abdominal PainGastrointestinal disorders0/300/290/292/341/320/320/32
PyrexiaGeneral disorders0/301/290/290/340/320/320/32
Upper Respiratory Tract InfectionInfections and infestations0/301/290/290/340/320/320/32
FlatulenceGastrointestinal disorders0/300/291/291/341/321/320/32
DiarrheaGastrointestinal disorders1/301/291/291/341/320/320/32
RashSkin and subcutaneous tissue disorders1/300/290/290/340/320/320/32
VomitingGastrointestinal disorders0/300/290/290/341/320/320/32
HypothyroidismEndocrine disorders0/300/290/290/340/321/320/32
COVID-19Infections and infestations0/300/290/290/340/321/320/32

Baseline characteristics

Full Analysis Set (FAS) includes all randomized and treated subjects who have the baseline assessment and at least one post randomization assessment of the primary efficacy measure of weekly SBM frequency.

Age, Customized
Age, Customized(Participants)0.5 mg Plecanatide1.0 mg Plecanatide - Group AMatching Placebo - Group A1.0 mg Plecanatide - Group B2.0 mg Plecanatide3.0 mg PlecanatideMatching Placebo - Group BTotal
Age Group — Group A: Age 6 to 11302929000088
Age Group — Group B: Age 12 to <1800034323232130
Sex: Female, Male
Sex: Female, Male(Participants)0.5 mg Plecanatide1.0 mg Plecanatide - Group AMatching Placebo - Group A1.0 mg Plecanatide - Group B2.0 mg Plecanatide3.0 mg PlecanatideMatching Placebo - Group BTotal
Female16151520202020126
Male1414141412121292
Race (NIH/OMB)
Race (NIH/OMB)(Participants)0.5 mg Plecanatide1.0 mg Plecanatide - Group AMatching Placebo - Group A1.0 mg Plecanatide - Group B2.0 mg Plecanatide3.0 mg PlecanatideMatching Placebo - Group BTotal
American Indian or Alaska Native00000000
Asian00101002
Native Hawaiian or Other Pacific Islander00100001
Black or African American425662227
White26272228253030188
More than one race00000000
Unknown or Not Reported00000000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)0.5 mg Plecanatide1.0 mg Plecanatide - Group AMatching Placebo - Group A1.0 mg Plecanatide - Group B2.0 mg Plecanatide3.0 mg PlecanatideMatching Placebo - Group BTotal
Hispanic or Latino23272325242728177
Not Hispanic or Latino726985441
Unknown or Not Reported00000000
Region of Enrollment
Region of Enrollment(Participants)0.5 mg Plecanatide1.0 mg Plecanatide - Group AMatching Placebo - Group A1.0 mg Plecanatide - Group B2.0 mg Plecanatide3.0 mg PlecanatideMatching Placebo - Group BTotal
United States30292934323232218
Height at Screening (m)
Height at Screening (m)(meters)0.5 mg Plecanatide1.0 mg Plecanatide - Group AMatching Placebo - Group A1.0 mg Plecanatide - Group B2.0 mg Plecanatide3.0 mg PlecanatideMatching Placebo - Group BTotal
Mean1.37 ± 0.1361.36 ± 0.1351.38 ± 0.1311.63 ± 0.0911.60 ± 0.0971.58 ± 0.0791.63 ± 0.0861.51 ± 0.159
Weight at Screening
Weight at Screening(kilograms)0.5 mg Plecanatide1.0 mg Plecanatide - Group AMatching Placebo - Group A1.0 mg Plecanatide - Group B2.0 mg Plecanatide3.0 mg PlecanatideMatching Placebo - Group BTotal
Mean37.53 ± 11.98039.55 ± 15.11838.79 ± 17.07066.35 ± 22.40260.72 ± 14.05058.21 ± 16.22363.60 ± 16.6252.73 ± 20.231
BMI at Screening
BMI at Screening(kg/m^2)0.5 mg Plecanatide1.0 mg Plecanatide - Group AMatching Placebo - Group A1.0 mg Plecanatide - Group B2.0 mg Plecanatide3.0 mg PlecanatideMatching Placebo - Group BTotal
Mean19.82 ± 4.96120.87 ± 6.67819.64 ± 5.59024.85 ± 7.12923.66 ± 4.46023.26 ± 6.23023.74 ± 4.86722.385 ± 6.035
08

Study locations

35 sites
  • Bausch Site 178
    Saraland, Alabama 36571, United States
  • Bausch Site 176
    Scottsdale, Arizona 85258, United States
  • Bausch Site 160
    Corona, California 92879, United States
  • Bausch Site 147
    Garden Grove, California 92845, United States
  • Bausch Site 142
    Los Angeles, California 90036, United States
  • Bausch Site 143
    Ventura, California 93003, United States
  • Bausch Site 175
    Aurora, Colorado 80012, United States
  • Bausch Site 197
    Washington D.C., District of Columbia 20016, United States
  • Bausch Site 135
    Doral, Florida 33122, United States
  • Bausch Site 190
    Hialeah, Florida 33012, United States
  • Bausch Site 150
    Miami, Florida 33126, United States
  • Bausch Site 130
    Miami, Florida 33134, United States
  • Bausch Site 165
    Miami, Florida 33136, United States
  • Bausch Site 110
    Tampa, Florida 33607, United States
  • Bausch Site 174
    Atlanta, Georgia 30315, United States
  • Bausch Site 132
    Atlanta, Georgia 30342, United States
  • Bausch Site 148
    Stockbridge, Georgia 30281, United States
  • Bausch Site 115
    Evansville, Indiana 47715, United States
  • Bausch Site 139
    Sioux City, Iowa 51106, United States
  • Bausch Site 192
    Bowling Green, Kentucky 42101, United States
  • Bausch Site 172
    Covington, Louisiana 70433, United States
  • Bausch Site 180
    Crowley, Louisiana 70526, United States
  • Bausch Site 112
    Lafayette, Louisiana 70508, United States
  • Bausch Site 220
    Omaha, Nebraska 68134, United States
  • Bausch Site 145
    Akron, Ohio 44308, United States
  • Bausch Site 194
    Cleveland, Ohio 44106, United States
  • Bausch Site 111
    Knoxville, Tennessee 37922, United States
  • Bausch Site 195
    Austin, Texas 78723, United States
  • Bausch Site 225
    Cedar Park, Texas 78613, United States
  • Bausch Site 173
    Dallas, Texas 75243, United States
  • Bausch Site 193
    Houston, Texas 77030, United States
  • Bausch Site 170
    Houston, Texas 77087, United States
  • Bausch Site 140
    San Antonio, Texas 78215, United States
  • Bausch Site 120
    Newport News, Virginia 23606, United States
  • Bausch Site 146
    Bellevue, Washington 98007, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Nov 2024, 76 months.

Results were first posted in Dec 2025, 1 year 1 month after primary completion.

Of 24 industry-sponsored phase 2 interventional studies under Constipation, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 29. This study's 76 months is above that.

Counting every sponsor, half of 41 studies reached it within 20 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2018
First posted
Jul 24, 2018
StartActual
Jun 30, 2018
Primary completionActual
Nov 25, 2024
CompletionActual
Nov 25, 2024
Results first posted
Dec 31, 2025
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03596905
Responsible party
Sponsor
First posted
Jul 24, 2018
Start date
Jun 30, 2018
Primary completion
Nov 25, 2024
Completion
Nov 25, 2024
Results posted
Dec 31, 2025
Last update
Dec 31, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Plecanatide

Start the discussion